Expert Insights

At the 2022 San Antonio Breast Cancer Symposium, Ariella Hanker, PhD, discusses the biological mechanisms behind CDK4/6 inhibitor resistance and novel approaches being developed to overcome this resistance in patients with breast cancer.

Traci Kruer, PhD, discusses data from a phase 1/2 trial showing XPO1 overexpression is a mechanism of resistance to eprenetapopt and 5-azacitidine and can be therapeutically exploited to treat patients with TP53-mutated myeloid malignancies.

Caspian Oliai, MD, MS, provides insight into novel strategies in reducing GVHD, including orca-t cell therapy and post-transplant cyclophosphamide.

Shernan G Holtan, MD, discusses findings from a phase 3 study on GVHD prophylaxis in reduced intensity conditioning, which she presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans, LA.

At the 2023 ASCO Gastrointestinal Symposium, Josep Tabernero, MD, shared results from the phase 3 trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory colorectal cancer.

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.

At the 2023 ASCO Gastrointestinal Symposium, Kohei Shitara, MD, presents first results from a phase 3 study evaluating zolbetuximab plus modified FOLFOX6 in the first-line setting for patients with claudin-18.2-positive/HER2-negative locally...

At the 2022 San Antonio Breast Cancer Symposium, Joanne Kotsopoulos, PhD, discusses the risks certain hormonal exposures can pose for BRCA1/2 carriers.